Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Neurobiology of Opioid Dependence: 5 - 5
This study has been completed.
Sponsors and Collaborators: National Institute on Drug Abuse (NIDA)
Yale University
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00000196
  Purpose

The purpose of this study is to determine the effect of acute naltrexone pretreatment on the response to yohimbine in healthy volunteers.


Condition Intervention Phase
Opioid-Related Disorders
Drug: Naltrexone
Phase II

Drug Information available for: Naltrexone Naltrexone hydrochloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Double-Blind, Placebo Control
Official Title: Neurobiology of Opioid Dependence: 5

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Behavioral, physiological, neuroendocrine response to yohimbine

Estimated Enrollment: 0
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000196

Locations
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
Investigators
Principal Investigator: Marc I Rosen, M.D. VA Connecticut Healthcare System
  More Information

Study ID Numbers: NIDA-00191-5, K20-00191-5
Study First Received: September 20, 1999
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00000196  
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Mental Disorders
Naltrexone
Substance-Related Disorders
Disorders of Environmental Origin
Opioid-Related Disorders

Additional relevant MeSH terms:
Sensory System Agents
Therapeutic Uses
Physiological Effects of Drugs
Narcotic Antagonists
Peripheral Nervous System Agents
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009